Spectrum Pharmaceuticals

OverviewSuggest Edit

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operation. The Company and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

TypePublic
Founded2002
HQHenderson, NV, US
Websitesppirx.com
Employee Ratings2.9
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)146(-37%)
Job Openings49
Revenue (FY, 2020)$0
Share Price (Jul 2021)$3.3(+4%)
Cybersecurity ratingCMore

Key People/Management at Spectrum Pharmaceuticals

Joseph W. Turgeon

Joseph W. Turgeon

President and Chief Executive Officer, Director
William L. Ashton

William L. Ashton

Chairman of the Board
Kurt A. Gustafson

Kurt A. Gustafson

Executive Vice President and Chief Financial Officer
Francois J. Lebel

Francois J. Lebel

Executive Vice President and Chief Medical Officer
Keith M. McGahan

Keith M. McGahan

Executive Vice President, Chief Legal Officer and Corporate Secretary
Thomas J. Riga

Thomas J. Riga

Executive Vice President, Chief Operating Officer and Chief Commercial Officer
Show more

Spectrum Pharmaceuticals Office Locations

Spectrum Pharmaceuticals has offices in Henderson, Cambridge and Irvine
Henderson, NV, US (HQ)
11500 S Eastern Ave #240
Cambridge, MA, US
1 Main St
Irvine, CA, US
157 Technology Dr
Show all (3)

Spectrum Pharmaceuticals Financials and Metrics

Spectrum Pharmaceuticals Revenue

USD

Net income (Q1, 2021)

(35.7m)

EBIT (Q1, 2021)

(33.7m)

Market capitalization (28-Jul-2021)

532.2m

Closing stock price (28-Jul-2021)

3.3

Cash (31-Mar-2021)

69.5m
Spectrum Pharmaceuticals's current market capitalization is $532.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

193.0m255.0m155.9m186.8m162.6m146.4m128.4m109.3m

Revenue growth, %

30%(27%)7%

Cost of goods sold

33.8m7.9m4.4m

Gross profit

159.1m138.6m124.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

45.4m51.0m59.9m68.7m69.0m29.3m33.2m42.4m40.1m46.9m48.0m38.6m45.0m28.6m43.9m33.9m33.4m29.1m34.3m36.4m30.5m24.2m25.3m

Cost of goods sold

8.1m8.8m8.7m11.6m11.2m1.3m2.2m2.2m2.1m2.1m

Gross profit

37.2m42.2m51.2m57.1m57.9m42.6m31.7m31.2m27.0m32.2m36.4m30.5m

Gross profit Margin, %

82%83%86%83%84%97%93%93%93%94%100%100%
USDQ2, 2011

Financial Leverage

2 x
Show all financial metrics

Spectrum Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

1

Phase III Trials Products

3
Show all operating metrics

Spectrum Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Spectrum Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Spectrum Pharmaceuticals Online and Social Media Presence

Embed Graph

Spectrum Pharmaceuticals Company Culture

  • Overall Culture

    C+

    76/100

  • CEO Rating

    B

    77/100

  • Compensation

    D

    56/100

Learn more on Comparably

Spectrum Pharmaceuticals News and Updates

Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease

LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has entered a licensing agreement with Spectrum Pharmaceuticals for Renazorb (lanthanum...

Thinking about buying stock in Spectrum Pharmaceuticals, Sohu.com, Southwest Airlines, resTORbio, or Vaxart Inc?

NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPPI, SOHU, LUV, TORC, and VXRT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Spectrum Pharmaceuticals shares slide 57% after lung cancer trial misses goals

Shares of biopharmaceutical company Spectrum Pharmaceuticals Inc. slid more than 57% Thursday to mark their worst performance in 17 years, after the company said a mid-stage trial of a treatment for non-small cell lung cancer (NSCLC) missed its main goal.

Global Peripheral T-Cell Lymphoma (PTCL) Market to 2026 - Celgene Leads Industry Sponsors with the Highest Number of Clinical Trials, Followed by Spectrum Pharmaceuticals

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Peripheral T-Cell Lymphoma (PTCL)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical...

Global HDAC (histone deacetylase) Inhibitors Market to 2023 Featuring Celgene, Merck & Co, Novartis, Shenzhen Chipscreen Biosciences, & Spectrum Pharmaceuticals

DUBLIN, April 26, 2019 /PRNewswire/ -- The "Global HDAC (histone deacetylase) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023. The development of novel drug...

Aurobindo Pharma to acquire portfolio of seven marketed oncology injectables products from Spectrum Pharmaceuticals

Acrotech Biopharma LLC (Acrotech), a wholly-owned subsidiary of Aurobindo Pharma USA Inc., which in turn a wholly-owned subsidiary of Aurobindo Pharma, will be acquiring the portfolio on a debt free and cash free basis. This acquisition is in line with our strategy to commercialize innovative propri…
Show more

Spectrum Pharmaceuticals Blogs

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 1, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) is “on site” for the ROLONTIS® (eflapegrastim) manufacturing

Spectrum Pharmaceuticals to Present Data for Poziotinib in Patients with Brain Metastases at the Upcoming 2021 ASCO Annual Meeting

HENDERSON, Nev. --(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June

Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June Content Import Thu, 05/27/2021 - 07:02 Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June May 27, 2021 at 7:00 AM EDT This release is a backf…

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance FDA pre-approval inspection at the ROLONTIS ® manufacturing facility scheduled for May 2021 Management to host webcast and

Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update Content Import Thu, 05/06/2021 - 07:00 Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update May 6, 2021 at 7:00 AM EDT …
Show more

Spectrum Pharmaceuticals Frequently Asked Questions

  • When was Spectrum Pharmaceuticals founded?

    Spectrum Pharmaceuticals was founded in 2002.

  • Who are Spectrum Pharmaceuticals key executives?

    Spectrum Pharmaceuticals's key executives are Joseph W. Turgeon, William L. Ashton and Kurt A. Gustafson.

  • How many employees does Spectrum Pharmaceuticals have?

    Spectrum Pharmaceuticals has 146 employees.

  • Who are Spectrum Pharmaceuticals competitors?

    Competitors of Spectrum Pharmaceuticals include Celltrion Healthcare, Jiangsu Hansoh Pharmaceutical Group and 3sbio.

  • Where is Spectrum Pharmaceuticals headquarters?

    Spectrum Pharmaceuticals headquarters is located at 11500 S Eastern Ave #240, Henderson.

  • Where are Spectrum Pharmaceuticals offices?

    Spectrum Pharmaceuticals has offices in Henderson, Cambridge and Irvine.

  • How many offices does Spectrum Pharmaceuticals have?

    Spectrum Pharmaceuticals has 3 offices.